tiprankstipranks
pc:troge

Trogenix

Trogenix is a pioneering biotechnology company focused on developing innovative cancer therapies through its proprietary Odysseus® platform. The company specializes in creating precision genetic medicines that target aggressive, treatment-resistant cancers by delivering potent combination payloads that kill cancer cells and stimulate the immune system, while sparing healthy tissue. Trogenix's lead program targets glioblastoma, with additional efforts in colorectal cancer liver metastases and other solid tumors, aiming to transform cancer treatment paradigms with potentially curative "one-and-done" therapies.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$70M
Total Amount Raised$70M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$70M
Latest Funding Amount$70M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Oct 08, 2025
Series A
$70.00M

Related News and Analysis